SCHEMBL8011114

SCHEMBL8011114

Cn1c(-c2ccccn2)nc(-c2ccc(-c3nnco3)cc2)c1Sc1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.50
NOTUM Q6P988 3/20 0.43
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPK14 Q16539 5/20 0.37
MAPK13 O15264 3/20 0.37
GCGR P47871 3/20 0.37
MAPK12 P53778 3/20 0.37
MAPK11 Q15759 3/20 0.37
KDM4E B2RXH2 3/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALDH1A1 P00352 4/20 0.36
HTT P42858 2/20 0.36
MEN1 O00255 1/20 0.36
PPP1CA P62136 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPT P10636 3/20 0.36
DCTPP1 Q9H773 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8001993 0.92 FAAH (0.52) FAAHNOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL8004010 0.91 FAAH (0.61) FAAHNOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL8002857 0.90 FAAH (0.48) FAAHNOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL8005530 0.89 FAAH (0.49) FAAHNOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL12106423 0.88 FAAH (0.49) FAAHNOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL8004675 0.87 FAAH (0.42) FAAHNOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL8001935 0.85 FAAH (0.47) FAAHNOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL8001939 0.84 FAAH (0.42) FAAHNOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL12106397 0.82 FAAH (0.43) FAAHNOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL1304556 0.82 NOTUM (0.43) FAAHNOTUMNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
WO-2009152025-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK & CO., INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH FAAH, FAAH2, HNMT FAAH 1/4885NOTUM 397/4885NPC1 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.